North America Radioactive Tracer Market Forecast to 2030

North America Radioactive Tracer Market Forecast to 2030 – Regional Analysis – by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others), and End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, and Others)

Send Enquiry

$2,485$3,885

Description

The North America radioactive tracer market was valued at US$ 8,139.16 million in 2022 and is expected to reach US$ 29,331.01 million by 2030; it is estimated to grow at a CAGR of 17.4% from 2022 to 2030.

Increasing Use of Nuclear Imaging Techniques fuel the North America Hair Extension Market

PET and SPECT are among the nuclear medicine radiology modalities employed in clinical settings. Their use is increasing as they offer accurate detection, localization, and characterization of diseases. Ionizing radiation for diagnosis and treatment benefits millions of patients globally. Radiation in medicine helps earlier diagnosis and often offers less invasive treatments for human diseases. Advanced radiation technology has opened new horizons in diagnostic and nuclear medicine, radiotherapy, and interventional radiology. According to World Health Organization, over 3,600 million diagnostic radiology examinations are performed, 37 million nuclear medicine procedures are carried out, and 7.5 million radiotherapy treatments are given annually. The development and introduction of new radiopharmaceuticals for PET/CT and SPECT/CT procedures, which are used in novel clinical applications such as neurology and orthopedics, and the growing accuracy of different tumor staging methods contribute to the growth of the radioactive tracer market. For instance, newly introduced cardiac radiopharmaceuticals such as flurpiridaz F-18 and ammonia N-13 help in more precise imaging of cardiovascular conditions. Thus, constant technological advancements for improving the quality and efficacy of nuclear imaging techniques favor the growth of the radioactive tracer market.

North America Radioactive Tracer Market Overview

The North America radioactive tracer market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America radioactive tracer market. Rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development in advanced diagnosis method are the key factors propelling the market for radioactive tracer. Also, the increasing use of nuclear imaging techniques are favoring market expansion.

North America Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Million)

North America Radioactive Tracer Market Segmentation

The North America radioactive tracer market is segmented based on tracer type, test type, end user, application, and country. Based on tracer type, the North America radioactive tracer market is segmented into technetium-99m & Tc-97m, iodine-131, iron-59, lutetium-171, rubidium (Rb-82) chloride & ammonia (N-13), scandium-46, seaborgium-269, hassium-269, Gallium citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), phosphorus-32 & chromium-51, thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and others. The others segment held the largest market share in 2022.

Based on test type, the North America radioactive tracer market is segmented into PET, SPECT, and others. The SPECT segment held the largest market share in 2022.

Based on end user, the North America radioactive tracer market is segmented into hospitals & clinics, diagnostic centers, academic & research institutes, and others. The hospitals & clinics segment held the largest market share in 2022.

Based on application, the North America radioactive tracer market is segmented into oncology, pulmonary, neurology, cardiology, and others. The oncology segment held the largest market share in 2022.

Based on country, the North America radioactive tracer market is segmented into the US, Canada, and Mexico. The US dominated the North America radioactive tracer market share in 2022.

Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, Blue Earth Diagnostics Limited, General Electric Co, and IBA Radiopharma Solutions are some of the leading players operating in the North America radioactive tracer market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 17.4% CAGR, the North America Radioactive Tracer Market is Speculated to be worth US$ 29,331.01 million by 2030, says the research team

According to the research team’ research,, the North America radioactive tracer market was valued at US$ 8,139.16 million in 2022 and is expected to reach US$ 29,331.01 million by 2030, registering a CAGR of 17.4% from 2022 to 2030. Rising prevalence of chronic diseases and increasing use of nuclear imaging techniques are the critical factors attributed to the North America radioactive tracer market expansion.

Increasing aging population, changing social behavior, rising adoption of a sedentary lifestyle, and accelerating urbanization are the key factors boosting the prevalence of obesity and other chronic diseases such as diabetes. Further, studies have long established that genes can cause chronic conditions such as cardiovascular disease (CVD), diabetes, obesity, Alzheimer’s disease (AD), and depression. According to the National Council on Aging, Inc., 80% of adults aged 65 and above suffer from at least one chronic condition, while 68% suffer from two or more. According to the Centers for Disease Control and Prevention (CDC), in 2020, ~6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people suffered from two or more chronic conditions. CVDs, such as atherosclerosis, angina pectoris, and acute myocardial infarction, caused due to hectic lifestyles have become significant causes of mortality worldwide. As per the data provided by the WHO, CVDs are the predominant cause of death worldwide, recording estimated 17.9 million deaths each year. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can lead to various complications in different body parts and increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are among the major complications associated with diabetes. According to the International Diabetes Federation (IDF), diabetic cases in North America are expected to reach 62 million by 2045 from 46 million in 2017. The data further reported that 425 million people suffered from diabetes in 2017, and the count is expected to reach 629 million worldwide by 2045. The disease prevalence will likely increase by nearly 35% during the forecast period. Thus, an effective examination is a must for properly treating chronic diseases; hence, nuclear substances are used for diagnosis and examination purposes. These nuclear substances are used in diagnostic tests such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) to diagnose chronic diseases such as neurological, cardiovascular, chronic lung, and chronic kidney diseases. the availability of several radiotracer across the globe makes it selection easy depending on the type of disease and its prognosis. Thus, the increasing incidences of chronic diseases are surging the demand for radioactive tracer, positively favoring market expansion.

On the contrary, short shelf-life of radioactive tracer hurdles the growth of North America radioactive tracer market.

Based on tracer type, the North America radioactive tracer market is categorized into technetium-99m & Tc-97m, iodine-131, iron-59, lutetium-171, rubidium (Rb-82) chloride & ammonia (N-13), scandium-46, seaborgium-269, hassium-269, Gallium citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), phosphorus-32 & chromium-51, thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and others. The others segment held 64.1% market share in 2022, amassing US$ 5,215.06 million. It is projected to garner US$ 17,788.12 million by 2030 to expand at 16.6% CAGR during 2022–2030.

Based on test type, the North America radioactive tracer market is categorized into PET, SPECT, and others. The SPECT segment held 44.5% share of North America radioactive tracer market in 2022, amassing US$ 3,618.01 million. It is projected to garner US$ 12,991.18 million by 2030 to expand at 17.3% CAGR during 2022–2030.

Based on end user, the North America radioactive tracer market is categorized into hospitals & clinics, diagnostic centers, academic & research institutes, and others. The hospitals & clinics segment held 70.1% share of North America radioactive tracer market in 2022, amassing US$ 5,704.25 million. It is projected to garner US$ 20,579.86 million by 2030 to expand at 17.4% CAGR during 2022–2030.

Based on application, the North America radioactive tracer market is categorized into oncology, pulmonary, neurology, cardiology, and others. The oncology segment held 63.2% share of North America radioactive tracer market in 2022, amassing US$ 5,146.83 million. It is projected to garner US$ 18,053.87 million by 2030 to expand at 17.0% CAGR during 2022–2030.

Based on country, the North America radioactive tracer market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% share of North America radioactive tracer market in 2022. It was assessed at US$ 6,899.57 million in 2022 and is likely to hit US$ 24,605.78 million by 2030, exhibiting a CAGR of 17.2% during 2022–2030.

Key players operating in the North America radioactive tracer market are Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, Blue Earth Diagnostics Limited, General Electric Co, and IBA Radiopharma Solutions, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America radioactive tracer market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the North America radioactive tracer market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America radioactive tracer market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Radioactive Tracer Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Rising Prevalence of Chronic Diseases
4.1.2 Increasing Use of Nuclear Imaging Techniques
4.2 Market Restraints
4.2.1 Short Shelf-Life of Radioactive Tracer
4.2.2 Availability of Substitutes to Nuclear Diagnostic Imaging Procedures
4.3 Market Opportunities
4.3.1 New Initiatives for Radioactive Tracer R&D
4.4 Future Trends
4.4.1 Use of Radioactive Tracer in Cancer Diagnosis
4.5 Impact Analysis:
5. Radioactive Tracer Market – North America Market Analysis
5.1 Radioactive Tracer Market Revenue (US$ Mn), 2022 – 2030
6. North America Radioactive Tracer Market – Revenue and Forecast to 2030 – by Tracer Types
6.1 Overview
6.2 Radioactive Tracer Market Revenue Share, by Tracer Types 2022 & 2030 (%)
6.3 Technetium 99m and TC-97m
6.3.1 Overview
6.3.2 Technetium 99m and TC-97m: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Iodine 131
6.4.1 Overview
6.4.2 Iodine 131: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Iron 59
6.5.1 Overview
6.5.2 Iron 59: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Lutetium- 171
6.6.1 Overview
6.6.2 Lutetium- 171: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.7 RB82 and ammonia N-13
6.7.1 Overview
6.7.2 RB82 and ammonia N-13: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.8 Scandium 46
6.8.1 Overview
6.8.2 Scandium 46: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.9 Seaborgium-269
6.9.1 Overview
6.9.2 Seaborgium-269: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.10 Hassium -269
6.10.1 Overview
6.10.2 Hassium -269: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.11 Gallium Citrate GA 67
6.11.1 Overview
6.11.2 Gallium Citrate GA 67: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.12 PSMA GA68
6.12.1 Overview
6.12.2 PSMA GA68: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.13 FDDNP (F-18) and FDOPA (f-18)
6.13.1 Overview
6.13.2 FDDNP (F-18) and FDOPA (f-18): Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.14 Phosphorus 32 and Chromium -51
6.14.1 Overview
6.14.2 Phosphorus 32 and Chromium -51: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.15 Thallium-201
6.15.1 Overview
6.15.2 Thallium-201: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.16 F-18 FDG
6.16.1 Overview
6.16.2 F-18 FDG: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.17 F-18 FAPI
6.17.1 Overview
6.17.2 F-18 FAPI: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.18 GA 68 FAPI
6.18.1 Overview
6.18.2 GA 68 FAPI: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.19 F-18 PSMA
6.19.1 Overview
6.19.2 F-18 PSMA: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.20 DOTATOC/DOTANOC/DOTATATE Ga 68
6.20.1 Overview
6.20.2 DOTATOC/DOTANOC/DOTATATE Ga 68: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.21 Others
6.21.1 Overview
6.21.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Radioactive Tracer Market – Revenue and Forecast to 2030 – by Test Type
7.1 Overview
7.2 Radioactive Tracer Market Revenue Share, by Test Type 2022 & 2030 (%)
7.3 PET
7.3.1 Overview
7.3.2 PET: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
7.4 SPECT
7.4.1 Overview
7.4.2 SPECT: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Radioactive Tracer Market – Revenue and Forecast to 2030 – by Application.
8.1 Overview
8.2 Radioactive Tracer Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Pulmonary
8.4.1 Overview
8.4.2 Pulmonary: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Neurology
8.5.1 Overview
8.5.2 Neurology: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Cardiology
8.6.1 Overview
8.6.2 Cardiology: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Radioactive Tracer Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Radioactive Tracer Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Centers
9.4.1 Overview
9.4.2 Diagnostic Centers: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Academic and Research Institutes
9.5.1 Overview
9.5.2 Academic and Research Institutes: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Radioactive Tracer Market – Country Analysis
10.1 North America Radioactive Tracer Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Radioactive Tracer Market, by Country
10.1.2.1 US
10.1.2.1.1 Overview
10.1.2.1.2 US Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.1.3 US Radioactive Tracer Market, by Tracer Types
10.1.2.1.4 US Radioactive Tracer Market, by Test Type
10.1.2.1.5 US Radioactive Tracer Market, by Application
10.1.2.1.6 US Radioactive Tracer Market, by End-User
10.1.2.2 Canada
10.1.2.2.1 Overview
10.1.2.2.2 Canada Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.2.3 Canada Radioactive Tracer Market, by Tracer Types
10.1.2.2.4 Canada Radioactive Tracer Market, by Test Type
10.1.2.2.5 Canada Radioactive Tracer Market, by Application
10.1.2.2.6 Canada Radioactive Tracer Market, by End-User
10.1.2.3 Mexico
10.1.2.3.1 Overview
10.1.2.3.2 Mexico Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.3.3 Mexico Radioactive Tracer Market, by Tracer Types
10.1.2.3.4 Mexico Radioactive Tracer Market, by Test Type
10.1.2.3.5 Mexico Radioactive Tracer Market, by Application
10.1.2.3.6 Mexico Radioactive Tracer Market, by End-User
11. Radioactive Tracer Market Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Radioactive Tracer Market, Key Company Profiles
12.1 Rotem Industries Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Invicro LLC
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Cardinal Health Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Newcastle University
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Novartis AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Curium
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Blue Earth Diagnostics Limited
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 General Electric Co
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 IBA Radiopharma Solutions
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Radioactive Tracer Market Segmentation
Table 2. Principal Radionuclides Used in Radioactive Tracer
Table 3. US Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Tracer Types
Table 4. US Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Test Type
Table 5. US Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Application
Table 6. US Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – End-User
Table 7. Canada Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Tracer Types
Table 8. Canada Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Test Type
Table 9. Canada Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Application
Table 10. Canada Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – End-User
Table 11. Mexico Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Tracer Types
Table 12. Mexico Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Test Type
Table 13. Mexico Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – Application
Table 14. Mexico Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn) – End-User
Table 15. Organic Developments Done by Companies
Table 16. Inorganic Developments Done by Companies
Table 17. Glossary of Terms, North America Radioactive Tracer Market

LIST OF FIGURES

Figure 1. North America Radioactive Tracer Market Segmentation, By Country
Figure 2. North America Radioactive Tracer Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Radioactive Tracer Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Radioactive Tracer Market Revenue Share, by Tracer Types 2022 & 2030 (%)
Figure 6. Technetium 99m and TC-97m: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Iodine 131: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Iron 59: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Lutetium- 171: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. RB82 and ammonia N-13: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Scandium 46: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Seaborgium-269: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Hassium -269: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Gallium Citrate GA 67: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. PSMA GA68: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. FDDNP (F-18) and FDOPA (f-18): North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Phosphorus 32 and Chromium -51: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Thallium-201: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. F-18 FDG: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. F-18 FAPI: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. GA 68 FAPI: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. F-18 PSMA: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. DOTATOC/DOTANOC/DOTATATE Ga 68: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America Radioactive Tracer Market Revenue Share, by Test Type 2022 & 2030 (%)
Figure 26. PET: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. SPECT: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Others: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. North America Radioactive Tracer Market Revenue Share, by Application 2022 & 2030 (%)
Figure 30. Oncology: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Pulmonary: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Neurology: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Cardiology: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Others: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. North America Radioactive Tracer Market Revenue Share, by End User 2022 & 2030 (%)
Figure 36. Hospitals and Clinics: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diagnostic Centers: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. Academic and Research Institutes: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 39. Others: North America Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. North America Radioactive Tracer Market, by Country 2022 ($Mn)
Figure 41. North America Radioactive Tracer Market, By Key Countries, 2022 And 2030 (%)
Figure 42. US Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn)
Figure 43. Canada Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn)
Figure 44. Mexico Radioactive Tracer Market Revenue And Forecast to 2030 (US$ Mn)

The List of Companies – North America Radioactive Tracer Market

o Rotem Industries Ltd
o Invicro LLC
o Cardinal Health Inc
o Newcastle University
o Novartis AG
o Curium
o Blue Earth Diagnostics Limited
o General Electric Co
o IBA Radiopharma Solutions

Reviews

There are no reviews yet.

Be the first to review “North America Radioactive Tracer Market Forecast to 2030”